Even with recent scientific and technological advances, from the decoding of the human genome to stem cell technology, the promise of medical progress remains unfulfilled for ALS/MND patients and their loved ones. There is currently only one drug; FDA approved in 1995, to systemically treat ALS—and it merely prolongs survival by two to four months.
Why? There are many factors, including the sheer complexity of the disease, but intellectual, structural, and financial obstacles have also prevented any significant breakthroughs.
Scientists require collaborators with diverse research expertise, skills, and specializations to advance their discoveries. Yet, too often researchers work in isolation or in competition with one another without producing results.
That is why ALS Worldwide regularly brings together top experts from all sectors of medical research to increase dialogue, encourage partnerships and accelerate the pace of discovery and innovation. We are passionate in our commitment to people affected by ALS/MND and actively seek out the best and the brightest, those known for their scientific excellence, collaborative approach, patient-centric focus and sense of urgency.
ALS Worldwide funds, facilitates and shares groundbreaking research that helps everyone understand the disease’s causes, determine how best to prevent it, and discover ways to cure it as quickly as possible. While ALS Worldwide is a small nonprofit organization, we believe our focused and flexible approach can make a big impact on research.